Your session is about to expire
← Back to Search
Duobrii for Scalp Psoriasis
Study Summary
This trial tests a lotion to improve hair growth, reduce scalp itch, and improve scalp psoriasis in 12 weeks. Patients' perceptions of the lotion's value are also assessed.
- Scalp Psoriasis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Active Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants is the maximum capacity for this clinical research?
"Affirmative, the information posted on clinicaltrials.gov confirms that this medical experiment is presently recruiting individuals. The study was originally published on June 1st 2023 and has since been updated for a final time on May 14th 2023; it seeks to enroll twenty patients from one trial site."
Has this intervention been validated by the FDA?
"Due to the fact that this medication has been approved as part of a Phase 4 clinical trial, it can be assumed with some confidence that its safety level is at least 3."
Are there any opportunities available for enrollment in this scientific research?
"The clinical trial, which was initially created on June 1st 2023 and modified for the last time on May 14th 2023, is currently open to participants according to clinicaltrials.gov's data."
Share this study with friends
Copy Link
Messenger